血清HE4、CA125和ROMA指数对卵巢肿瘤良恶性评价及疗效和预后判断分析  

Evaluation of Serum HE4,CA125 and ROMA Index for Benign and Malignant Ovarian Tumors and Analysis of Efficacy and Prognosis

作　　者：蒙国煌 梁远晴 邱振华[1] 邓波[1] MENG Guo-huang;LIANG Yuan-qing;QIU Zhen-hua;DENG Bo(Department of Laboratory Medicine,Gaozhou People's Hospital,Gaozhou,Guangdong Province,525200 China;Department of Obstetrics and Gynecology,Gaozhou Maternity and Child Health Hospital,Gaozhou,Guangdong Province,525200 China)

机构地区：[1]高州市人民医院检验科,广东高州525200 [2]高州市妇幼保健院妇产科,广东高州525200

出　　处：《中外医疗》2020年第24期162-164,176,共4页China & Foreign Medical Treatment

摘　　要：目的探究CA125、血清HE4以及ROMA指数对卵巢肿瘤良性、恶性的评估以及疗效和预后判断分析。方法方便抽取2018年6月—2019年6月于该院进行诊治的91例卵巢肿瘤患者纳入研究,其中60例是良性肿瘤患者、31例是恶性肿瘤患者,观察并测定良性肿瘤患者、恶性肿瘤患者的CA125、血清HE4以及ROMA指数。结果与良性肿瘤患者相比,卵巢恶性肿瘤患者的血清HE4、CA125、ROMA指数显著更高[恶性肿瘤(349.83±328.02)pmol/L、(1922.55±1 537.32)U/mL、(78.29±21.10)%,良性肿瘤(63.78±50.27)pmol/L、(82.02±59.48)U/mL、(15.34±12.23)%,差异有统计学意义(t=6.639、9.309、18.028,P<0.05);治疗前后,卵巢恶性肿瘤患者的血清HE4、CA125、ROMA指数有显著差别,治疗后更低,[治疗前为262.90(111.61,366.80)pmol/L、804.73(264.52,1 896.74)U/mL、89.51(72.82,97.43)%,治疗后为41.72(15.22,76.40)pmol/L、51.22(27.72,108.21)U/mL、35.72(14.42,62.31)%],差异有统计学意义(P<0.05);肿瘤转移或复发后,卵巢恶性肿瘤患者血清HE4、CA125、ROMA指数显著升高[治疗前224.40 (124.52,350.41)pmol/L、1 436.03(392.5,2 413.80)U/m L、87.05 (77.40,97.30)%,治疗后为57.51 (43.20,83.14)pmol/L、29.11 (16.01,167.50)U/mL、10.22(5.31,25.10)%],差异有统计学意义(P<0.05)。结论 CA125、血清HE4以及ROMA指数联合检测可有效评估卵巢肿瘤良性、恶性,且对其疗效与预后判断有一定的参考意义。Objective To explore the evaluation of benign and malignant ovarian tumors by CA125,serum HE4 and ROMA index,as well as the analysis of curative effect and prognosis.Methods A total of 91 patients with ovarian tumors who were diagnosed and treated in our hospital from June 2018 to June 2019 were enrolled in the study,of which 60 were benign tumor patients and 31 were malignant tumor patients,and observed and measured benign tumor patients and malignant tumor patients,serum HE4,CA125 and ROMA index.Results Compared with patients with benign tumors,patients with ovarian malignant tumors had significantly higher,serum HE4,CA125 and ROMA indexes,and the data difference was statistically significant[malignant tumor(349.83±328.02)pmol/L,(1922.55±1537.32)U/mL,(78.29±21.10)%;benign tumor(63.78±50.27)pmol/L、(82.02±59.48)U/mL、(15.34±12.23)%,the difference was statistically significant(t=6.639,9.309,18.028,P<0.05).Before and after treatment,there were significant differences in serum HE4,CA125 and ROMA in patients with ovarian malignancies,and the serum indexes were lower after treatment,[before treatment,262.90(111.61,366.80)pmol/L,804.73(264.52,1896.74)U/mL,89.51(72.82,97.43)%,and after treatment,41.72(15.22,76.40)pmol/L,51.22(27.72,108.21)U/mL,35.72(14.42,62.31)%].The difference was statistically significant(P<0.05).After tumor metastasis or recurrence,serum HE4,CA125,and ROMA were significantly increased in patients with ovarian malignancies[224.40(124.52,350.41)pmol/L,1436.03(392.5,2413.80)U/mL,87.05(77.40,97.30)%before treatment,and 57.51(43.20,83.14)pmol/L,29.11(16.01,167.50)U/mL,10.22(5.31,25.10)%after treatment].The difference was statistically significant(P<0.05).Conclusion The combined detection of CA125,serum HE4 and ROMA index can effectively assess the benign and malignant ovarian tumors,and has certain reference significance for the judgment of its efficacy and prognosis.

关 键 词：血清HE4 CA125 ROMA指数 卵巢肿瘤 预后效果 

分 类 号：R730.43[医药卫生—肿瘤] R737.31[医药卫生—临床医学]